Following adults with stable COPD over time to describe their characteristics
Follows adults with stable COPD during routine care to describe their characteristics.
Plain-language title generated from the registry record
Registry title: Prospective Dynamic Cohort Study of Phenotypic Profiles in Patients With Chronic Obstructive Pulmonary Disease
Key facts
- Where
- Bordeaux, Lille, Nancy, Paris, Reims, and Saint-Etienne, FranceSee the 6 sites
Where in France
- CHU BordeauxBordeaux, FranceTaking people
- CHU LilleLille, FranceTaking people
- Chu Nancy-BraboisNancy, FranceTaking people
- Hôpital CochinParis, FranceTaking people
- CHU ReimsReims, FranceTaking people
- CHU Saint-EtienneSaint-Etienne, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Initiatives Bronchopneumopathie Chronique Obstructive (BPCO)
- Trial code
- NCT07627763
- Record updated
- 4 June 2026
- Original description
This prospective, multicenter, real-world observational cohort study will describe phenotypic profiles, patient characteristics, and treatments in adults with stable chronic obstructive pulmonary disease (COPD). The profiles observed in the current cohort will be compared with those of patients recruited between 2005 and 2018 in the previous COPD-BPCO 1 cohort. Patients will be followed for at least 3 years as part of routine care, with no study-specific visit or treatment.Read full original descriptionShow less
Prospective Multicenter Dynamic Cohort Study to Evaluate Phenotypic Profiles of Subjects With Chronic Obstructive Pulmonary Disease (COPD-BPCO 2 Study)
This prospective, multicenter, real-world observational cohort study will describe phenotypic profiles, patient characteristics, and treatments in adults with stable chronic obstructive pulmonary disease (COPD). The profiles observed in the current cohort will be compared with those of patients recruited between 2005 and 2018 in the previous COPD-BPCO 1 cohort. Patients will be followed for at least 3 years as part of routine care, with no study-specific visit or treatment.
Inclusion: Age 18 years or older; Stable COPD, defined as no exacerbation requiring treatment during the previous 4 weeks; Confirmed COPD diagnosis based on post-bronchodilator FEV1/FVC < 70%.
Exclusion: Main diagnosis of bronchiectasis, asthma, or any other significant respiratory disease; Patients under legal protection; Pregnant women.